BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia
Published: 23 Jun 2020
Views: 521
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses BLIN-01 trial which looks at blinatumomab use during consolidation in adult patients with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia.
He outlines the trial design, results and toxicity profile.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Related Videos
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
Lenalidomide combination for multiple myeloma
Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France
1 Oct 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
25 Sep 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
